Breakthrough Genomics Joins Forces with the PRECEDE Consortium to Help Accelerate the Early Detection of Pancreatic Cancer
SAN DIEGO, Nov. 21, 2024 /PRNewswire/ — Breakthrough Genomics, a leader in the clinical analysis of genomic data and early cancer diagnostics, announced today its collaboration with the PRECEDE Consortium to advance the clinical evaluation and adoption of its BT-Reveal™ Early Pancreatic Cancer Test.
Excerpt from the Press Release:
This groundbreaking blood test, which is powered by Singlera’s MethylTitan technology, can detect the earliest signs of pancreatic cancer in circulating cell-free DNA, often before symptoms appear. Utilizing patented DNA methylation technology, the test received the FDA’s coveted Breakthrough Device Designation and is currently available for high-risk patients through Breakthrough Genomics which operates a CAP and CLIA-certified clinical lab in Southern California.
Early detection is critical for pancreatic cancer as most cases are diagnosed at an advanced stage when treatment options are limited. This has made pancreatic cancer one of the most deadly types of cancers with a mortality rate that has remained largely unchanged despite gains in other cancer types.
The partnership with PRECEDE offers Breakthrough Genomics access to a network of the world’s foremost pancreatic cancer researchers, clinicians, and high-risk centers. Led by world-renown surgeon and scientist, Dr. Diane Simeone, the PRECEDE Consortium is conducting the largest longitudinal study of its kind, with over 7,000 patients enrolled across 54 leading institutions.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?